Accelerating Medicines Partnership-Autoimmune and Immunologic Disease Tissue Research Core Admin Supplement: Preclinical Studies in Sjogren's
Accelerating Medicines Partnership-Autoimmune and Immunologic Disease Tissue Research Core Admin Supplement: Preclinical Studies in Sjogren's
批准号:
10834635
负责人:
Joel Marvin Guthridge
金额:
$146.04万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-03-23 至 2026-12-31
关键词:
AccelerationAddressAffectAlgorithmsAntibodiesAntigensArthritisAutoantibodiesAutoimmune DiseasesAutomobile DrivingAutophagocytosisB-Cell LymphomasB-Lymphocyte SubsetsB-LymphocytesBiological MarkersBiological Response Modifier TherapyBiopsyBloodCCR6 geneCD4 Positive T LymphocytesCRISPR interferenceCRISPR-mediated transcriptional activationCXCR3 geneCell DeathCell SeparationCellsChromiumChronicClassificationClinicClinicalClinical TrialsCluster AnalysisConduct Clinical TrialsCytometryDataData SetDevelopmentDiagnosisDiagnosticDiagnostic testsDiseaseDrynessEconomic BurdenEnhancersEnsureEpithelial CellsEpitheliumExclusionFatigueFibroblastsFibrosisFlow CytometryFunctional disorderGeneticGenomicsGlandGoalsHLA-DR AntigensHaplotypesHeterogeneityHumanImageImmuneImmune System DiseasesImmunologyIn VitroIndividualInterviewInvestigationLabial Salivary GlandLip structureLungLymphocyteLymphomaMachine LearningMapsMedicineMethodsMolecularMonitorMultiomic DataNatureNeuropathyPainPathogenicityPathologyPatient RecruitmentsPatientsPeripheral Blood Mononuclear CellPersonsPhenotypePlasmaPopulationPositioning AttributeProbabilityProcessProteinsProteomeProteomicsResearchResearch PersonnelRheumatismRheumatologyRiskRoleSS-A antibodiesSalivaSalivary GlandsSerumSialadenitisSjogren&aposs SyndromeSortingSourceSurrogate MarkersT-LymphocyteT-Lymphocyte SubsetsTechnologyTelephoneTestingTissuesTranscriptional RegulationUntranslated RNAVasculitisXerostomiaantibody diagnosticautoimmune exocrinopathycell typeclinical developmentclinical heterogeneitycohortdata reductiondeep learningdiagnostic accuracydiagnostic assaydiagnostic biomarkerdisorder controleye drynessfeature selectiongenetic associationgradient boostinghealth care settingsimprovedinsightmachine learning methodmeetingsmultidisciplinarymultiple omicsmultiplex diagnosticsnano-stringneural networknew therapeutic targetnoninvasive diagnosisnovelpatient subsetspreclinical studyprogrammed cell death protein 1random forestrheumatologistrisk variantscreeningsingle-cell RNA sequencingsupport vector machinetooltranscriptometranscriptomics
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT ABSTRACT
Sjögren’s syndrome (SS) is an incapacitating rheumatic disease typified by severe dry eyes and mouth, often
including arthritis, debilitating fatigue, pulmonary involvement, neuropathy, vasculitis and malignant lymphoma.
The personal and economic burdens ($35 billion/year in the US) are high, and there is no effective biologic
therapy. Lack of understanding of basic disease processes, molecular underpinnings of patient heterogeneity,
and effective diagnostic biomarkers have hindered the development of effective biologic therapies and conduct
of successful clinical trials. This is especially true for patients lacking anti-Ro antibodies (Ro– SS) who require a
salivary gland biopsy for classification. We are in a unique position to study the differences between Ro+ and
Ro– SS. In our carefully phenotyped cohort, nearly 40% of SS patients meeting current classification criteria lack
diagnostic anti-Ro autoantibodies. Our Ro– SS cases have more glandular, articular, and pulmonary involvement
than Ro+ SS cases, yet these patients are often not diagnosed by rheumatologists or included in clinical trials.
Herein, we leverage our multidisciplinary team of investigators with expertise in rheumatology, immunology,
genomics/genetics, as well as our carefully phenotyped cohort of 668 SS cases and 925 non-SS sicca patients
to address these deficiencies. The project is based on compelling preliminary data identifying common and
unique features in both Ro+ and Ro– SS groups and will study a common set of 60 Ro+ SS cases, 60 Ro– SS
cases, and 24 healthy controls. Aim 1 will develop and apply an autoantibody-based diagnostic test for Ro– and
Ro+ SS and leverage salivary gland proteomics, spectral flow cytometry, imaging mass cytometry, and functional
studies to clarify the role of T and B cell subsets in disease. Aim 2 will employ single cell RNA-seq of PBMC and
sorted cells studied in Projects 1 and 2, identify chromosomal interactions in primary salivary gland epithelial
cells, study functional effects of Ro+ and Ro– SS risk alleles and long non-coding RNAs using CRISPR
interference or activation for enhancers, and use feature selection and machine learning to identify sources of
heterogeneity between Ro+ and Ro– SS.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms of New-Onset Autoimmunity/Longitudinal Immune Systems Analysis (MONA-LISA)
-
批准号:10655219
-
项目类别:
-
资助金额:$129.11万
-
财政年份:2023
-
负责人:Joel Marvin Guthridge
-
依托单位:
Accelerating Medicines Partnership-Autoimmune and Immunologic Disease Tissue Research Core
-
批准号:10687729
-
项目类别:
-
资助金额:$14.13万
-
财政年份:2022
-
负责人:Joel Marvin Guthridge
-
依托单位:
Accelerating Medicines Partnership-Autoimmune and Immunologic Disease Tissue Research Core
-
批准号:10452026
-
项目类别:
-
资助金额:$505.0万
-
财政年份:2022
-
负责人:Joel Marvin Guthridge
-
依托单位:
Accelerating Medicines Partnership-Autoimmune and Immunologic Disease Tissue Research Core
-
批准号:10596177
-
项目类别:
-
资助金额:$728.96万
-
财政年份:2022
-
负责人:Joel Marvin Guthridge
-
依托单位:
Human Phenotyping Core
-
批准号:10478211
-
项目类别:
-
资助金额:$36.85万
-
财政年份:2018
-
负责人:Joel Marvin Guthridge
-
依托单位:
Human Phenotyping Core
-
批准号:10016171
-
项目类别:
-
资助金额:$36.85万
-
财政年份:2018
-
负责人:Joel Marvin Guthridge
-
依托单位:
Human Phenotyping Core
-
批准号:10704390
-
项目类别:
-
资助金额:$34.1万
-
财政年份:2018
-
负责人:Joel Marvin Guthridge
-
依托单位:
Ikaros family genes and lupus susceptibility across ethnically diverse populations
-
批准号:9770772
-
项目类别:
-
资助金额:$82.71万
-
财政年份:2018
-
负责人:Joel Marvin Guthridge
-
依托单位:
Human Phenotyping Core
-
批准号:10251965
-
项目类别:
-
资助金额:$36.85万
-
财政年份:2018
-
负责人:Joel Marvin Guthridge
-
依托单位:
Ikaros family genes and lupus susceptibility across ethnically diverse populations
-
批准号:10238826
-
项目类别:
-
资助金额:$78.17万
-
财政年份:2018
-
负责人:Joel Marvin Guthridge
-
依托单位:
CORE E: BIOREPOSITORY CORE
-
批准号:8359799
-
项目类别:
-
资助金额:$3.88万
-
财政年份:2011
-
负责人:Joel Marvin Guthridge
-
依托单位:
CORE F: SERUM ANALYTE AND BIOMARKER CORE
-
批准号:8364935
-
项目类别:
-
资助金额:$20.73万
-
财政年份:2011
-
负责人:Joel Marvin Guthridge
-
依托单位:
OK COBRE: GENETICS OF B LYMPHOCYTE SIGNALING IN LUPUS
-
批准号:7960574
-
项目类别:
-
资助金额:$12.59万
-
财政年份:2009
-
负责人:Joel Marvin Guthridge
-
依托单位:
PEPTIDE SYNTHESIS CORE
-
批准号:7959377
-
项目类别:
-
资助金额:$7.23万
-
财政年份:2009
-
负责人:Joel Marvin Guthridge
-
依托单位:
Genetic and Functional Analysis of LYN Alleles Associated with Lupus
-
批准号:7938654
-
项目类别:
-
资助金额:$7.96万
-
财政年份:2009
-
负责人:Joel Marvin Guthridge
-
依托单位:
Genetic and Functional Analysis of LYN Alleles Associated with Lupus
-
批准号:7680457
-
项目类别:
-
资助金额:$7.75万
-
财政年份:2008
-
负责人:Joel Marvin Guthridge
-
依托单位:
CORE: PEPTIDE SYNTHESIS CORE FACILITY
-
批准号:7720053
-
项目类别:
-
资助金额:$7.06万
-
财政年份:2008
-
负责人:Joel Marvin Guthridge
-
依托单位:
OK COBRE: GENETICS OF B LYMPHOCYTE SIGNALING IN LUPUS
-
批准号:7720937
-
项目类别:
-
资助金额:$13.73万
-
财政年份:2008
-
负责人:Joel Marvin Guthridge
-
依托单位:
Phenotyping Core
-
批准号:8444002
-
项目类别:
-
资助金额:$38.34万
-
财政年份:2007
-
负责人:Joel Marvin Guthridge
-
依托单位:
Phenotyping Core
-
批准号:9136767
-
项目类别:
-
资助金额:$38.34万
-
财政年份:2007
-
负责人:Joel Marvin Guthridge
-
依托单位:
海外基金